Spark Therapeutics Inc (ONCE) : Rock Springs Capital Management Lp scooped up 15,000 additional shares in Spark Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 625,000 shares of Spark Therapeutics Inc which is valued at $39,143,750.Spark Therapeutics Inc makes up approximately 2.47% of Rock Springs Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Casdin Capital reduced its stake in ONCE by selling 69,000 shares or 42.46% in the most recent quarter. The Hedge Fund company now holds 93,500 shares of ONCE which is valued at $5,855,905. Spark Therapeutics Inc makes up approx 4.55% of Casdin Capital’s portfolio.Geode Capital Management boosted its stake in ONCE in the latest quarter, The investment management firm added 12,413 additional shares and now holds a total of 162,987 shares of Spark Therapeutics Inc which is valued at $8,991,993. Sg Americas Securities added ONCE to its portfolio by purchasing 3,127 company shares during the most recent quarter which is valued at $146,625.Alps Advisors Inc boosted its stake in ONCE in the latest quarter, The investment management firm added 547 additional shares and now holds a total of 39,036 shares of Spark Therapeutics Inc which is valued at $1,833,131. Spark Therapeutics Inc makes up approx 0.02% of Alps Advisors Inc’s portfolio. Capital Fund Management S.a. sold out all of its stake in ONCE during the most recent quarter. The investment firm sold 6,800 shares of ONCE which is valued $327,352.
Spark Therapeutics Inc closed down -2.49 points or -4.30% at $55.39 with 4,64,515 shares getting traded on Monday. Post opening the session at $57.89, the shares hit an intraday low of $54.55 and an intraday high of $57.9 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Spark Therapeutics Inc reported $-1.07 EPS for the quarter, missing the analyst consensus estimate by $ -0.06 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-1.01. The company had revenue of $1.30 million for the quarter, compared to analysts expectations of $1.25 million. During the same quarter in the previous year, the company posted $-0.70 EPS.
Many Wall Street Analysts have commented on Spark Therapeutics Inc. Stifel Initiated Spark Therapeutics Inc on Sep 2, 2016 to “Buy”, Price Target of the shares are set at $73.
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.